GRACEcast ALL Subjects audio and video

Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 31 Jul 2014 19:00:00 +0000

Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.

Management of Rare Kidney Tumors

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 29 Jul 2014 19:00:00 +0000

What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.

Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 27 Jul 2014 19:00:00 +0000

The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.

NanoString Treatment for Kidney Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 24 Jul 2014 19:00:00 +0000

NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.

Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 22 Jul 2014 19:00:00 +0000

Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

How is the Heng Criteria Applied to Kidney Cancer Patients?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 20 Jul 2014 19:00:00 +0000

Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 17 Jul 2014 19:00:00 +0000

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

What is PD1 and PDL1 in Kidney Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 15 Jul 2014 19:00:00 +0000

Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.

Zykadia for ALK Positive Lung Cancer: New Drug, New Hope

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 13 Jul 2014 19:00:00 +0000

The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.

No Clear Answer for Non-Clear Cell Kidney Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 10 Jul 2014 19:00:00 +0000

Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.

What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 08 Jul 2014 19:00:00 +0000

"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).

Treating Newly Diagnosed Kidney Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 06 Jul 2014 19:00:00 +0000

Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.

MET-Amplified Lung Cancer: A New Target for XALKORI?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 03 Jul 2014 19:00:00 +0000

Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.

The Hottest Thing in Late Stage Kidney Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 01 Jul 2014 19:00:00 +0000

Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.

CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 29 Jun 2014 19:00:00 +0000

Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.

The Promise of PD1 Inhibitors in Kidney Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 26 Jun 2014 19:00:00 +0000

Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.

FGFR and Its Role in Treating Squamous Cell Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 25 Jun 2014 19:00:00 +0000

Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.

AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 24 Jun 2014 19:00:00 +0000

EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.

What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 23 Jun 2014 19:00:00 +0000

"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.

What Is Non-Clear Cell Kidney Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 22 Jun 2014 19:00:00 +0000

Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.

The Promise of Immunotherapy in Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 18 Jun 2014 19:00:00 +0000

Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.

Does Gilotrif Help EGFR Positive Lung Cancer Patients?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 18 Jun 2014 19:00:00 +0000

An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.

Is Progression-Free Survival Meaningful?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 17 Jun 2014 19:37:27 +0000

Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?

DDR2 Mutations in Squamous Cell Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 16 Jun 2014 19:00:00 +0000

A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.

Does Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 12 Jun 2014 19:00:00 +0000

Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.

What is FGFR, and Could It Be a Valuable Target for Patients with Lung Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 11 Jun 2014 19:00:00 +0000

Dr. Joel Neal of Stanford University Medical Center talks about FGFR - fibroblast growth factor receptor - and how it can impact non-small cell lung cancer growth.

How Do We Make EGFR Inhibitors Work Better for Patients

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 09 Jun 2014 19:00:00 +0000

Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.

TH 302: New Drug May Make Tumors Less Resistant to Treatment

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 04 Jun 2014 21:47:45 +0000

Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.

Should We Do Broad Sequencing of All Lung Tumors?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 01 Jun 2014 19:00:00 +0000

How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.

How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 29 May 2014 19:00:00 +0000

Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.

Why Are Non-Mutated EGFR Genes Called "Wild Type?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 27 May 2014 19:00:00 +0000

When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes are called "wild type." February 2014.

Teaching the Immune System to Attack Lung Cancer Tumors

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 25 May 2014 19:00:00 +0000

Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.

Advice for Lung Cancer Patients: Know Thy Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 22 May 2014 19:00:00 +0000

What should lung cancer patients know about their disease? Dr. Jonathan Riess argues that patients should understand what type of lung cancer they have and which, if any, mutations their lung tumors may have. He explains why in this video.

Is It Necessary for Early Stage Lung Cancer Patients to Get Molecular Testing for Their Tumors?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 21 May 2014 17:20:39 +0000

If you were diagnosed with early stage lung cancer, should you receive molecular testing on your tumor in order to get targeted therapy? Dr. Joel Neal of Stanford University Medical Center discusses the reasons for and against it. February 2014.

Treating EGFR Patients After Tarceva Stops Working

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 19 May 2014 07:00:00 +0000

Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, but eventually it stops working. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center talks about the next generation EGFR inhibitors that may soon become available. February 2014.

Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive Non-small Cell Lung Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 15 May 2014 19:00:00 +0000

Dr. Joel Neal of Stanford University Medical Center discusses the SELECT clinical trial which studied early stage non-small cell lung cancer patients and whether or not Tarceva (erlotinib) would prevent disease recurrence. February 2014.

An Update on ECOG 1505: Will Avastin (Bevacizumab) Become Standard Treatment for Early Stage Lung Cancer Patients?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 14 May 2014 19:00:00 +0000

Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. February 2014.

Targeted Treatment for Lung Cancer After Progression

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 13 May 2014 19:00:00 +0000

Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute discusses whether or not patients on targeted therapies, such as EGFR inhibitors, should stay on those therapies after their cancers begin to grow again. February 2014.

Can Vaccines Fight Lung Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 12 May 2014 19:00:00 +0000

Dr. Charles Rudin of Memorial Sloan Kettering on the possibility of using vaccines to fight lung cancer. February 2014.

CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 11 May 2014 19:00:00 +0000

Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.

Why Do We Call Them "Small Cell Lung Cancer" and "Non-Small Cell Lung Cancer"?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 08 May 2014 19:00:00 +0000

Dr. Cathy Pietanza of Memorial Sloan Kettering explains how small cell lung cancer and non-small cell lung cancer are differentiated. February 2014.

Targeting the RAF Pathway in Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 07 May 2014 19:00:00 +0000

Dr. Charles Rudin of Memorial Sloan Kettering talks about RAF and other genetic mutations that play a role in the growth of lung cancer. February 2014.

Is It Possible to Test Lung Tumors Without Doing a Biopsy?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 06 May 2014 19:00:00 +0000

Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute talks about exciting new developments which will allow oncologists to test patients' lung tumors without invasive biopsies. February 2014.

What Are PARP Inhibitors, and Might They Improve Outcomes in Small Cell Lung Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 05 May 2014 19:00:00 +0000

Dr. Charles Rudin of Memorial Sloan Kettering on how PARP inhibitors may benefit patients with small cell lung cancer. February 2014.

New Insights into Small Cell Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 04 May 2014 19:00:00 +0000

Dr. Cathy Pietanza of Memorial Sloan Kettering on the new avenues of research into the treatment of small cell lung cancer. February 2014.

In What Clinical Setting Should Immunotherapies Be Developed?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 01 May 2014 23:24:42 +0000

Dr. Charles Rudin of Memorial Sloan Kettering discusses immune therapies that show promise in fighting lung cancer. February 2014.

Maintenance Therapy in Small Cell Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 17 Apr 2014 21:52:52 +0000

Dr. Cathy Pietanza of Memorial Sloan Kettering on current and emerging treatments that are given to help keep small cell lung cancer from coming back after it has disappeared following initial therapy. February 2014.

LDE225 and Small Cell Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 17 Apr 2014 21:52:15 +0000

Dr. Cathy Pietanza of Memorial Sloan Kettering talks about a drug currently in clinical trials that may successfully treat small cell lung cancer. February 2014.

Is There a Silver Bullet for Small Cell Lung Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 17 Apr 2014 21:51:43 +0000

Dr. Cathy Pietanza of Memorial Sloan Kettering discusses potential areas of success in the treatment of small cell lung cancer. February 2014.

Advice for Newly Diagnosed Small Cell Lung Cancer Patients

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 17 Apr 2014 21:51:09 +0000

Dr. Cathy Pietanza of Memorial Sloan Kettering offers suggestions for newly diagnosed small cell lung cancer patients. February 2014.

PARP Inhibitors in Small Cell Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 17 Apr 2014 21:50:23 +0000

Dr. Cathy Pietanza of Memorial Sloan Kettering talks about the role of PARP inhibitors in the treatment of small cell lung cancer. February 2014.

What's the Status and Potential Utility of Cabozantinib in Lung Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 17 Apr 2014 21:49:45 +0000

Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can help patients with lung cancer. February 2014.

MK-3475 and its Efficacy in Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 17 Apr 2014 21:49:08 +0000

Dr. Edward Garon discusses what researchers are learning about MK-3475, an immune therapy treatment currently in clinical trial. February 2014.

How Do the Different Immune Checkpoint Inhibitors in Lung Cancer Compare?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 17 Apr 2014 21:48:20 +0000

Dr. Edward Garon warns that it is still too early to compare which immune therapies will be more effective in treating lung cancer.February 2014.

Do you see PARP inhibitors as a single drug therapy or more in a combination setting?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 17 Apr 2014 21:46:42 +0000

Dr. Cathy Pietanza of Memorial Sloan Kettering discusses whether PARP treatments can be taken alone or if they must be taken with other drugs. February 2014.

Late Stage Oropharynx Cancer, Chemotherapy - Options and Practice (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 16 Apr 2014 03:15:31 +0000

Dr. Jared Weiss, University of North Carolina, discusses chemotherapy options and practice in late stage oropharynx cancer.

Late Stage Oropharynx Cancer, Chemotherapy - Options and Practice (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 16 Apr 2014 03:14:23 +0000

Dr. Jared Weiss, University of North Carolina, discusses chemotherapy options and practice in late stage oropharynx cancer.

ALK Positive Lung Cancer Forum 2014: Repeat Biopsies

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 04 Apr 2014 00:07:56 +0000

Why would an ALK lung cancer patient need a repeat biopsy? The doctors discuss the need for and frequency of repeat biopsies.

ALK Positive Lung Cancer Forum 2014: Next Generation ALK Inhibitors

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 04 Apr 2014 00:07:22 +0000

Several new treatments for ALK positive lung cancer patients are on the horizon. In this video, the doctors discuss them while patients in the audience share some of their experiences with side effects on various treatments.

ALK Positive Lung Cancer Forum 2014: Disease Progression While on Xalkori

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 04 Apr 2014 00:06:45 +0000

New treatments for ALK rearrangements are on the horizon. In this video, the doctors discuss how they determine whether or not they change treatments for their patients once they begin to show progression while on Xalkori (crizotinib).

ALK Positive Lung Cancer Forum 2014: Scanning for Progression

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 04 Apr 2014 00:05:28 +0000

How often should ALK patients receive scans to determine if their disease has progressed in various parts of the body?

ALK Positive Lung Cancer Forum 2014: Risk of Flare After Stopping Targeted Therapy

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 04 Apr 2014 00:04:46 +0000

The doctors discuss how patients can navigate the tricky waters of stopping therapy while avoiding painful and sometimes life-threatening flare.

ALK Positive Lung Cancer Forum 2014: Can I Pass ALK Onto My Children

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 04 Apr 2014 00:04:09 +0000

ALK positive lung cancer typically shows up in people do not appear to be at high risk for the disease, so is this something that a lung cancer patient can pass on to his or her children? The doctors discuss what research shows on this issue.

ALK Positive Lung Cancer Forum 2014: Testing for ALK

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 04 Apr 2014 00:03:21 +0000

Who should be tested for ALK? How is ALK tested and how reliable are the results? In this video, the doctors discuss several issues surrounding the issue of testing for ALK, including what the medical guidelines suggest for testing lung cancer patients.

ALK Positive Lung Cancer Forum 2014: Xalkori

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 04 Apr 2014 00:02:10 +0000

Xalkori (crizotinib) was one of the fastest approved drugs in cancer treatment history because of its high efficacy levels in ALK positive lung cancer patients. In this video, the doctors discuss what took place as it raced to approval.

ALK Positive Lung Cancer Forum 2014: ALK Rearrangements in Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 04 Apr 2014 00:00:52 +0000

The doctors discuss the history of ALK in lung cancer treatments and what the ALK rearragement means for patients.

Late Stage Oropharynx Cancer, Treatment and Side Effects (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 30 Mar 2014 23:51:09 +0000

Dr. Geoffrey Geiger, University of Pennsylvania, outlines the course of radiotherapy treatment and side effects for head and neck cancer.

Late Stage Oropharynx Cancer, Treatment and Side Effects (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 30 Mar 2014 23:50:25 +0000

Dr. Geoffrey Geiger, University of Pennsylvania, outlines the course of radiotherapy treatment and side effects for head and neck cancer.

Late Stage Oropharynx Cancer, Planning for External Beam Radiotherapy (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 30 Mar 2014 23:49:53 +0000

Dr. Geoffrey Geiger, University of Pennsylvania, discusses the process of planning radiotherapy for head and neck cancer.

Late Stage Oropharynx Cancer, Planning for External Beam Radiotherapy (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 30 Mar 2014 23:48:34 +0000

Dr. Geoffrey Geiger, University of Pennsylvania, discusses the process of planning radiotherapy for head and neck cancer.

Late Stage Oropharynx Cancer, Introduction and Management (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 30 Mar 2014 23:47:43 +0000

Dr. Geoffrey Geiger, University of Pennsylvania, provides an introduction to head and neck cancer and the human papilloma virus.

Late Stage Oropharynx Cancer, Introduction and Management (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 30 Mar 2014 23:46:48 +0000

Dr. Geoffrey Geiger, University of Pennsylvania, provides an introduction to head and neck cancer and the human papilloma virus.

Squamous Lung Cancer Part 5, Q and A Session (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 20 Dec 2013 08:35:45 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.

Squamous Lung Cancer Part 5, Q and A Session (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 20 Dec 2013 08:34:51 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.

Squamous Lung Cancer, Part 4: Immunotherapy (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 10 Dec 2013 23:43:54 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

Squamous Lung Cancer, Part 4: Immunotherapy (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 10 Dec 2013 23:43:17 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

Squamous Lung Cancer, Part 3: Treatment (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 08 Dec 2013 23:08:03 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.

Squamous Lung Cancer, Part 3: Treatment (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 08 Dec 2013 23:07:31 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.

Squamous Lung Cancer, Part 2: Genomic Testing (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 06 Dec 2013 18:03:17 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.

Squamous Lung Cancer, Part 2: Genomic Testing (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 06 Dec 2013 18:02:30 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.

Squamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 02 Dec 2013 23:40:44 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.

Squamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 02 Dec 2013 23:40:02 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.

Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 28 Sep 2013 00:39:00 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews novel approaches, including nab-paclitaxel with gemcitabine, in advanced pancreatic cancer.

Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 28 Sep 2013 00:39:00 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews novel approaches, including nab-paclitaxel with gemcitabine, in advanced pancreatic cancer.

Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 28 Sep 2013 00:38:24 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, discusses the history of and recent developments in chemotherapy for metastatic pancreatic cancer.

Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 28 Sep 2013 00:37:33 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, discusses the history of and recent developments in chemotherapy for metastatic pancreatic cancer.

Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 21 Sep 2013 00:45:05 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for post-operative (adjuvant) therapy for resectable pancreatic cancer.

Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 21 Sep 2013 00:44:27 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for post-operative (adjuvant) therapy for resectable pancreatic cancer.

Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 19 Sep 2013 07:14:57 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for pre-operative (neoadjuvant) therapy for resectable pancreatic cancer.

Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 19 Sep 2013 07:14:21 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer.

Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 09 Sep 2013 21:54:46 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer.

Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 09 Sep 2013 21:54:08 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer.

ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 04 Sep 2013 19:33:12 +0000

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.

ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 04 Sep 2013 19:32:39 +0000

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.

ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 31 Aug 2013 01:58:11 +0000

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.

ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 31 Aug 2013 01:56:45 +0000

ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 26 Aug 2013 23:57:00 +0000

Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.

ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 26 Aug 2013 23:56:00 +0000

ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 26 Aug 2013 23:55:19 +0000

Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.

ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 26 Aug 2013 23:54:27 +0000

ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 23 Aug 2013 18:49:01 +0000

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 23 Aug 2013 18:48:27 +0000

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 23 Aug 2013 18:47:36 +0000

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.

ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 23 Aug 2013 18:46:58 +0000

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.

ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 16 Aug 2013 21:20:31 +0000

Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.

ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 16 Aug 2013 21:19:55 +0000

Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.

ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 16 Aug 2013 21:19:15 +0000

Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.

ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 16 Aug 2013 21:18:30 +0000

ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 15 Aug 2013 23:44:28 +0000

Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.

ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 15 Aug 2013 23:43:53 +0000

Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.

Dr. Rosalyn Juergens: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 15 Aug 2013 06:30:05 +0000

Dr. Rosalyn Juergens, McMaster University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.

Dr. Greg Riely on "Which patients do you send molecular marker testing for, and what tests do you seek?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 15 Aug 2013 06:29:20 +0000

Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.

Chemotherapy for Pancreatic Cancer, Part 1: Background and Molecular Biology (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 14 Aug 2013 21:12:30 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the role of chemotherapy in pancreatic cancer, beginning with the molecular biology of pancreatic cancer.

Chemotherapy for Pancreatic Cancer, Part 1: Background and Molecular Biology (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 14 Aug 2013 21:11:33 +0000

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the role of chemotherapy in pancreatic cancer, beginning with the molecular biology of pancreatic cancer.

ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 14 Aug 2013 00:03:58 +0000

Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.

ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 14 Aug 2013 00:03:22 +0000

Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.

ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 13 Aug 2013 01:44:24 +0000

Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.

ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 13 Aug 2013 01:43:52 +0000

Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.

ASCO Lung Cancer Highlights, Part 2: Optimizing Radiation for Stage III NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 11 Aug 2013 02:16:36 +0000

Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.

ASCO Lung Cancer Highlights, Part 2: Optimizing Radiation for Stage III NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 11 Aug 2013 02:15:59 +0000

Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.

ASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 07 Aug 2013 05:09:05 +0000

Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.

ASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 07 Aug 2013 05:08:09 +0000

Dr. Bob Doebele: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 06 Aug 2013 22:43:25 +0000

Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

Dr. Philip Bonomi: Gefitinib and Later Generations of EGFR Inhibitors

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 06 Aug 2013 22:42:34 +0000

Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).

Dr. David Spigel on "Which molecular marker tests do you seek?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 29 Jul 2013 21:44:28 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, describes which molecular markers he seeks for NSCLC patients.

HPV in Head and Neck Cancer, Part 2: Caveats and Emerging Trials (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 22 Jul 2013 20:41:44 +0000

Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from recent trials and describes emerging research in this population.

HPV in Head and Neck Cancer, Part 2: Caveats and Emerging Trials (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 22 Jul 2013 20:41:12 +0000

HPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 22 Jul 2013 20:40:37 +0000

Dr. Jared Weiss from the University of North Carolina, Chapel Hill introduces us to the human papilloma virus and its role as a cause and relevant prognostic factor for head and neck cancer (HNSCC).

HPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 22 Jul 2013 20:40:03 +0000

GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly

Induction Chemotherapy for Head and Neck Cancer, Part 2: New Concepts Moving Forward (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 21 Jul 2013 17:42:56 +0000

Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.

Induction Chemotherapy for Head and Neck Cancer, Part 2: New Concepts Moving Forward (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 21 Jul 2013 17:42:20 +0000

Induction Chemotherapy for Head and Neck Cancer, Part 1: Defining the Challenges (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 18 Jul 2013 21:06:08 +0000

Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.

Induction Chemotherapy for Head and Neck Cancer, Part 1: Defining the Challenges (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 18 Jul 2013 21:05:30 +0000

Dr. Ravi Salgia: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 11 Jul 2013 06:39:49 +0000

Dr. Ravi Salgia, from the University of Chicago, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

Dr. Sarah Goldberg: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 11 Jul 2013 06:39:14 +0000

Dr. Sarah Goldberg gives her view on more widespread availability of new mutation tests, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.

Dr. Bob Doebele on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 11 Jul 2013 06:38:39 +0000

Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 11 Jul 2013 06:38:00 +0000

Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on.

Dr. Greg Riely: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 11 Jul 2013 06:37:17 +0000

Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.

Is there a place for maintenance therapy in extensive stage NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 04 Jul 2013 18:38:48 +0000

Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether the finding of improving progression-free survival with maintenance sorafenib for SCLC should change the standard of care for treatment of extensive stage disease.

How should we integrate new immunotherapies into treatment strategies for lung cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 04 Jul 2013 18:37:44 +0000

Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.

How do we approach acquired resistance to targeted therapies in lung cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 04 Jul 2013 18:36:29 +0000

Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.

What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 04 Jul 2013 18:35:27 +0000

Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.

Dr. Phil Bonomi: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 04 Jul 2013 18:27:19 +0000

Dr. Phil Bonomi, from Rush University, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 04 Jul 2013 18:26:33 +0000

Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

Can we target KRAS effectively in advanced NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 02 Jul 2013 06:43:49 +0000

Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 02 Jul 2013 06:41:38 +0000

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

Could BRAF be a new target in NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 27 Jun 2013 08:04:25 +0000

Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.

Are molecular markers just for NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 21 Jun 2013 20:27:38 +0000

Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.

Dr. David Spigel: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 21 Jun 2013 00:30:19 +0000

Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other lung cancer subtypes.

Dr. Heather Wakelee on "Which molecular marker tests do you seek?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 21 Jun 2013 00:29:45 +0000

Dr. Heather Wakelee, from Stanford University, describes which molecular markers she seeks for NSCLC patients.

Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 19 Jun 2013 23:09:43 +0000

Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.

Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 19 Jun 2013 23:09:09 +0000

Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.

Can we harness our immune system to fight NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 19 Jun 2013 01:01:58 +0000

Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 19 Jun 2013 01:01:14 +0000

Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.

Dr. Larry Einhorn: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 15 Jun 2013 23:05:14 +0000

Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.

Dr. Karen Kelly: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 15 Jun 2013 23:04:20 +0000

Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.

Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 15 Jun 2013 21:31:11 +0000

Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.

Do you need Avastin in first line and maintenance therapy in advanced NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 13 Jun 2013 00:45:22 +0000

Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta.

Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 12 Jun 2013 02:51:46 +0000

Dr. Phil Bonomi, from Rush University, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

Can we predict which patients will benefit from Tarceva based on a blood test?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 12 Jun 2013 02:05:57 +0000

Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.

Drs. Ross Camidge and Corey Langer: How Do You Make Use of a Broad Molecular Profile Brought by a Patient?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 11 Jun 2013 01:37:02 +0000

Drs. Ross Camidge and Corey Langer describe their practice when patients with advanced NSCLC bring them the results of broad molecular marker testing.

Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 10 Jun 2013 02:14:20 +0000

Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).

Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 09 Jun 2013 07:38:46 +0000

Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.

Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 09 Jun 2013 07:38:12 +0000

Is it possible to test for biomarkers in lung cancer on a national scale?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 07 Jun 2013 19:36:35 +0000

Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).

Dr. Greg Riely: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 04 Jun 2013 23:18:15 +0000

Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

Dr. Geoffrey Oxnard: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 04 Jun 2013 01:49:12 +0000

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

Dr. Rosalyn Juergens on "My Approach to Maintenance Therapy for Advanced NSCLC"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 04 Jun 2013 01:48:00 +0000

Dr. Rosalyn Juergens, McMaster University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

Dr. Sarah Goldberg on "Which patients do you send molecular marker testing for?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 30 May 2013 22:55:02 +0000

Dr. Sarah Goldberg from Yale Cancer Center describes which patients with advanced NSCLC she seeks molecular marker testing on.

Dr. Ravi Salgia: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 30 May 2013 22:54:25 +0000

Dr. Ravi Salgia from the University of Chicago discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.

Dr. Antoinette Wozniak on Small Cell Lung Cancer: Introduction, Diagnosis, and Staging (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 30 May 2013 07:12:13 +0000

Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.

Dr. Antoinette Wozniak on Small Cell Lung Cancer: Introduction, Diagnosis, and Staging (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 30 May 2013 07:11:40 +0000

Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.

Dr. David Spigel: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 28 May 2013 23:34:04 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, gives his view on more widespread availability of new mutation tests.

Dr. Heather Wakelee: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 28 May 2013 23:33:29 +0000

Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

Dr. Sumanta (Monty) Pal: What Are the Main Types of Kidney Cancer and Are They Managed Differently?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 24 May 2013 18:17:53 +0000

Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, describes the main types of kidney cancer and discusses the differences in their management

Dr. Greg Riely: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 24 May 2013 07:04:24 +0000

Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

Dr. Phil Bonomi: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 21 May 2013 04:46:06 +0000

Dr. Phil Bonomi, from Rush University, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

Dr. Karen Kelly: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 21 May 2013 04:45:24 +0000

Dr. Karen Kelly, of the University of California, Davis, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 20 May 2013 22:50:43 +0000

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 20 May 2013 22:50:12 +0000

GRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology, Canada

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 17 May 2013 07:41:09 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.

Dr. Rosalyn Juergens: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 17 May 2013 07:40:33 +0000

Dr. Rosalyn Juergens, McMaster University, discusses the question of widespread availability of new mutation tests under the Canadian health care system.

Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 17 May 2013 07:39:57 +0000

Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.

Dr. Heather Wakelee on "My Approach to Maintenance Therapy for Advanced NSCLC"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 17 May 2013 07:39:18 +0000

Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 17 May 2013 01:18:09 +0000

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 17 May 2013 01:17:22 +0000

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).

Dr. Sumanta (Monty) Pal: What Are the Options for Second Line Treatment of Kidney Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 15 May 2013 06:56:24 +0000

Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, explains the range of options and his approach to second line treatment of kidney cancer.

Dr. Larry Einhorn: Are You Optimistic That a Supercomputer Such as Watson Will Be Able To Improve Cancer Care?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 15 May 2013 06:55:45 +0000

Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, gives his view on whether a supercomputer such as Watson will be able to use complex algorithms to improve cancer care.

Dr. Ravi Salgia: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 13 May 2013 23:01:18 +0000

Dr. Ravi Salgia, University of Chicago, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 1): Potential Value of Molecular Staging (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 13 May 2013 19:59:34 +0000

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 1): Potential Value of Molecular Staging (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 13 May 2013 19:58:53 +0000

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).

Dr. Karen Kelly: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 11 May 2013 19:44:35 +0000

Dr. Karen Kelly, of the University of California, Davis expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

Dr. David Spigel: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 11 May 2013 19:43:52 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

Dr. Rosalyn Juergens: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 10 May 2013 23:50:45 +0000

Dr. Rosalyn Juergens, McMaster University, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

Dr. Sarah Goldberg on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 10 May 2013 07:18:31 +0000

Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?

Dr. Greg Riely on "My Approach to Maintenance Therapy for Advanced NSCLC"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 07 May 2013 01:25:00 +0000

Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

Dr. Phil Bonomi, How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 07 May 2013 01:24:00 +0000

Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.

Managing Pancreatic Cancer: Systemic Therapy for Localized Prostate Cancer (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 04 May 2013 21:21:40 +0000

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, explains the rationale and introduces the current standards and some potential variants for systemic therapy in patients with apparently localized pancreatic cancer.

Managing Pancreatic Cancer: Systemic Therapy for Localized Prostate Cancer (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 04 May 2013 21:21:00 +0000

Dr. Sumanta (Monty) Pal: What is the Role of Surgery in the Treatment of Metastatic Kidney Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 02 May 2013 02:30:36 +0000

Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, describes the role of surgery in the treatment of metastatic kidney cancer.

Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for, and what tests do you seek?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 02 May 2013 02:29:52 +0000

Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on, and the particular markers they prioritize.

Dr. Larry Einhorn: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 01 May 2013 04:49:15 +0000

Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, gives his view on more widespread availability of new mutation tests.

Dr. Ravi Salgia on the CollabRx System for Matching Patients with Mutations to Clinical Trials

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 01 May 2013 04:48:38 +0000

Dr. Ravi Salgia, University of Chicago, describes the CollabRx system, which matches patients with particular mutations to appropriate clinical trials.

Dr. Geoffrey Oxnard on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 01 May 2013 04:48:03 +0000

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

Dr. Karen Kelly: Do You Continue a Treatment Beyond 4-6 Cycles to Exhaust its Benefit?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 01 May 2013 04:47:12 +0000

Dr. Karen Kelly, of the University of California, Davis, provides her thoughts on whether to continue an effective treatment beyond 4-6 cycles in an effort to exhaust the possible benefit from that treatment.

Dr. David Spigel: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 27 Apr 2013 21:57:13 +0000

David Spigel, Sarah Cannon Cancer Center, reviews how he discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

Dr. Sarah Goldberg: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 27 Apr 2013 21:56:28 +0000

Dr. Sarah Goldberg, from Yale Cancer Center, offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

Dr. Lecia Sequist on Multiplex Next Generation Sequencing and its Effect on Molecular Oncology Practice

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 27 Apr 2013 21:55:37 +0000

Dr. Lecia Sequist of Massachusetts General Hospital, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.

Dr. Rosalyn Juergens on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 27 Apr 2013 06:42:17 +0000

Dr. Rosalyn Juergens, McMaster University, addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential use in the adjuvant setting.

Dr. Greg Riely: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 26 Apr 2013 00:57:41 +0000

Dr. Greg Riely, from Memorial Sloan-Kettering, reviews his thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.

Drs. Ross Camidge and Corey Langer: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 24 Apr 2013 00:20:20 +0000

Drs. Ross Camidge and Corey Langer give their views on more widespread availability of new mutation tests.

Dr. Sumanta (Monty) Pal on the Role of Chemotherapy in the Treatment of Kidney Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 24 Apr 2013 00:19:37 +0000

Dr. Sumanta (Monty) Pal reviews the current role of chemotherapy in the treatment of kidney cancer.

Dr. Phil Bonomi, Rush University: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 18 Apr 2013 02:40:55 +0000

Dr. Phil Bonomi, from Rush University, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

Dr. Karen Kelly on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 18 Apr 2013 02:40:13 +0000

Dr. Karen Kelly of the University of California, Davis, provides her view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

Dr. David Spigel: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 18 Apr 2013 02:39:35 +0000

Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 18 Apr 2013 02:38:57 +0000

Dr. Sarah Goldberg from Yale Cancer Center describes the methods she uses to obtain tissue samples for molecular testing.

Dr. Lecia Sequist: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 18 Apr 2013 02:38:13 +0000

Dr. Lecia Sequist of Massachusetts General Hospital offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.

Managing Pancreatic Cancer: Surgery for Pancreatic Cancer, Its Complications, and the Importance of Surgical Volume (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 17 Apr 2013 02:25:32 +0000

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.

Managing Pancreatic Cancer: Surgery for Pancreatic Cancer, Its Complications, and the Importance of Surgical Volume (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 17 Apr 2013 02:24:54 +0000

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.

Dr. Rosalyn Juergens on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 12 Apr 2013 23:05:28 +0000

Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?

Dr. Larry Einhorn on "What Have Been the Most Significant Changes in Cancer Care over the Past Decade or Two?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 12 Apr 2013 23:04:00 +0000

Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, on what he sees as the most significant changes in cancer care in the last decade or two.

Dr. Ravi Salgia on "Which patients do you send molecular marker testing for, and what tests do you seek?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 12 Apr 2013 23:03:22 +0000

Dr. Ravi Salgia from University of Chicago describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.

Dr. Geoffrey Oxnard: Are Patients or Payers Objecting to Repeat Biopsy?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 12 Apr 2013 00:23:38 +0000

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, discusses the issue of patients or payers objecting to repeat biopsies.

Dr. Greg Riely on Muliplex Next Generation Sequencing and its Effect on Molecular Oncology Practice

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 11 Apr 2013 21:55:47 +0000

Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.

Dr. Phil Bonomi on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 11 Apr 2013 21:55:14 +0000

Dr. Phil Bonomi, from Rush University, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

Dr. Karen Kelly on "My Approach to Maintenance Therapy for Advanced NSCLC"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 10 Apr 2013 06:06:05 +0000

Dr. Karen Kelly of the University of California, Davis, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

Dr. David Spigel on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 10 Apr 2013 06:04:51 +0000

Dr. David Spigel addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.

Dr. Matthew Katz: Defining Resectability of Pancreatic Cancer (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 09 Apr 2013 01:47:01 +0000

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, discusses the factors that determine whether a person's pancreatic cancer is resectable and the importance of this factor in predicting clinical outcomes.

Dr. Matthew Katz: Defining Resectability of Pancreatic Cancer (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 09 Apr 2013 01:46:14 +0000

Dr. Sarah Goldberg: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 08 Apr 2013 19:19:25 +0000

Dr. Sarah Goldberg, Yale Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.

Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 08 Apr 2013 03:33:00 +0000

Drs. Ross Camidge and Corey Langer provide their perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 07 Apr 2013 00:15:38 +0000

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 07 Apr 2013 00:14:57 +0000

Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 05 Apr 2013 02:06:53 +0000

Dr. Lecia Sequist of Massachusetts General Hospital gives her view on more widespread availability of new mutation tests

Dr. Heather Wakelee: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 05 Apr 2013 02:06:16 +0000

Dr. Heather Wakelee from Stanford University offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.

Dr. Ravi Salgia: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 03 Apr 2013 00:12:20 +0000

Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.

Dr. Karen Reckamp on "Which patients do you send molecular marker testing for, and what tests do you seek?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 03 Apr 2013 00:11:40 +0000

Dr. Karen Reckamp from City of Hope Cancer Center in Duarte, CA describes which patients with advanced NSCLC she seeks molecular marker testing on, and the particular markers she prioritizes.

Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 31 Mar 2013 07:00:45 +0000

Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?

Dr. Geoffrey Oxnard on What Molecular Markers to Test for in Advanced NSCLC, and in Whom?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 31 Mar 2013 06:59:59 +0000

Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.

Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 30 Mar 2013 01:32:36 +0000

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.

Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 30 Mar 2013 01:31:55 +0000

Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 29 Mar 2013 23:46:42 +0000

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 29 Mar 2013 23:46:04 +0000

Dr. Matthew Katz: Staging Pancreatic Cancer (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 29 Mar 2013 01:18:28 +0000

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, reviews the general concept of cancer staging, the basic workup and staging of pancreatic cancer, and the implications of this process on treatment recommendations.

Dr. Matthew Katz: Staging Pancreatic Cancer (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 29 Mar 2013 01:17:33 +0000

Dr. Matthew Katz: Introduction to Pancreatic Cancer (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 29 Mar 2013 01:16:40 +0000

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, provides a general introduction to the form and function of the pancreas, along with a description of the magnitude of the impact of pancreatic cancer in the US.

Dr. Matthew Katz: Introduction to Pancreatic Cancer (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 29 Mar 2013 01:15:29 +0000

Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 29 Mar 2013 01:11:09 +0000

Dr. Sarah Goldberg addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.

Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 29 Mar 2013 01:10:18 +0000

Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over the next several years.

Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 25 Mar 2013 18:51:30 +0000

Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

Drs. Ross Camidge and Corey Langer: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 25 Mar 2013 06:47:40 +0000

Drs. Ross Camidge and Corey Langer offer their insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.

What is the Right Surgery for Early Stage Kidney Cancer?, by Dr. Monty Pal

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 25 Mar 2013 06:46:54 +0000

Dr. Sumanta (Monty) Pal reviews the questions on the role of surgery and what type of surgery to pursue for early stage kidney cancer.

Dr. David Spigel: We've Probably Made Maintenance Therapy More Complicated Than It Needs To Be

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 25 Mar 2013 06:42:49 +0000

Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 23 Mar 2013 03:04:55 +0000

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 23 Mar 2013 03:04:16 +0000

Dr. Alan Sandler: My Approach to Acquired Resistance for Targeted Therapies in Lung Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 21 Mar 2013 23:29:33 +0000

Dr. Alan Sandler from OHSU describes how acquired resistance to targeted therapies in lung cancer is similar to what is seen with chemo and comments on how he manages patients demonstrating gradual acquired resistance in advanced lung cancer.

Dr. Greg Riely on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 21 Mar 2013 23:28:57 +0000

Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

Dr. Ravi Salgia on "My Approach to Maintenance Therapy for Advanced NSCLC"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 20 Mar 2013 09:18:35 +0000

Dr. Ravi Salgia from University of Chicago provides his general strategy for patients with advanced non-small cell lung cancer who are candidates for maintenance therapy after first line treatment.

Dr. William Pao on "How Concerned Should We Be About Different Testing Methods, as well as the Heterogeneity of Different Biopsy Results from the Same Patient?"

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 20 Mar 2013 09:17:49 +0000

Dr. William Pao explains the caveats of molecular testing in terms of differences in testing methods through different laboratories and the heterogeneity of molecular findings in different biopsies even within the same individual with lung cancer.

Dr. Monty Pal on Leading Options for First Line Treatment of Advanced Kidney Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 19 Mar 2013 01:23:19 +0000

Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, explains the range of options and his approach to first line treatment of metastatic kidney cancer.

Dr. Larry Einhorn: What are the Biggest Challenges We Face in Delivering Effective Cancer Care in the Next Decade?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 19 Mar 2013 01:23:00 +0000

Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses leading challenges he sees for effective delivery of the best cancer care over the next decade.

Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 18 Mar 2013 23:59:00 +0000

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.

Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 18 Mar 2013 23:58:16 +0000

Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 14 Mar 2013 20:03:49 +0000

Dr. Geoffrey Oxnard conveys a central theme that the benefits of molecular oncology and optimal application of targeted therapies are dependent on a change in collecting tissue that works to obtain far more tissue than was historically required.

Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 14 Mar 2013 20:03:00 +0000

Dr. Heather Wakelee from Stanford University expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

Dr. Karen Reckamp: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 13 Mar 2013 00:37:06 +0000

Dr. Karen Reckamp, City of Hope Cancer Center, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

Dr. Rosalyn Juergens on Managing Acquired Resistance to Targeted Therapies for Advanced NSCLC

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 13 Mar 2013 00:36:22 +0000

Dr. Rosalyn Juergens, McMaster University, explains her approach to management of acquired resistance to targeted therapies in patients with a "driver mutation" and respond well initially to treatment.

Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (video)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 12 Mar 2013 22:30:29 +0000

Dr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robotic surgery to sub-lobar resections and other developments offering new promising alternatives.

Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (audio)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 12 Mar 2013 22:29:50 +0000

Dr. Sandler on Options for Maintenance Therapy: Switch, Continuation, or a Treatment Break?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 11 Mar 2013 01:03:39 +0000

Dr. Alan Sandler, Oregon Health and Science University, considers the various options for maintenance therapy as well as a potential treatment break after first line treatment of advanced non-small cell lung cancer.

Dr. Pal on the Role of Interleukin-2 (IL-2) in Advanced Kidney Cancer Today

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 11 Mar 2013 01:02:52 +0000

Dr. Sumanta (Monty) Pal of City of Hope Cancer Center discusses the current role of interleukin-2 (IL-2) in the context of many other treatment alternatives for metastatic renal cell carcinoma.

Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 11 Mar 2013 01:02:02 +0000

Dr. Karen Kelly of University of California, Davis, presents her current view on using molecular markers in early stage non-small cell lung cancer and explains the RADIANT study that she leads.

What Molecular Markers Do You Prioritize for Molecular Testing in Advanced NSCLC, and Who do you Test?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 10 Mar 2013 08:50:21 +0000

Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for.

Dr. Monty Pal: Reviewing Bladder Cancer Stages, the Role of Surgery, and the Potential Role of Chemotherapy for Localized Bladder Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 07 Mar 2013 07:09:23 +0000

Dr. Sumanta (Monty) Pal, City of Hope Cancer Center, summarizes basic stages of bladder cancer, value of surgery, and survival benefit of neoadjuvant (pre-operative) chemotherapy for higher risk muscle-invasive bladder cancer.

Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 07 Mar 2013 07:08:06 +0000

Dr. Sarah Goldberg notes that while maintenance therapy after first line treatment of advanced NSCLC is always worthy of a discussion, many patients need and benefit from a break from treatment to recover before pursuing additional therapy.

Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 07 Mar 2013 07:07:07 +0000

Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do "Reflex Testing"?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 07 Mar 2013 07:06:09 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, reviews which patients with lung cancer he feels should undergo molecular testing, as well as describing the potential value of immediate, reflex testing for molecular targets.

Dr. Larry Einhorn: Will Costs of Care Limit Our Ability to Deliver Cancer Treatments?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 05 Mar 2013 07:45:05 +0000

Dr. Larry Einhorn, Indiana University, expresses his concerns about the cost of developing cancer drugs and the challenge of paying for extremely expensive cancer treatments that are given in anticipation of modest clinical benefits.

Dr. Larry Einhorn: How Can We Replicate the High Cure Rates We've Achieved for Testicular Cancer in a Wide Range of Cancers?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 05 Mar 2013 07:44:26 +0000

Dr. Larry Einhorn, Indiana University, explains why some cancers such as testicular cancer can have such a high cure rate while most others are far more challenging to cure with our current systemic therapies, offering an optimistic view of the future.

Dr. Monty Pal on the Current Best Practices for Early Stage Kidney Cancer

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Tue, 05 Mar 2013 07:43:36 +0000

Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA describes optimal management of kidney cancer that is confined to the kidney, including surgery and the role of any additional post-surgical treatment.

Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 04 Mar 2013 04:28:07 +0000

Dr. Lecia Sequist provides her thoughts on how molecular oncology can soon begin affecting treatment plans for a broader range of patients with lung cancer, including those with squamous NSCLC and other lung cancer histologies.

Dr. Greg Riely: How I Use Molecular Marker Information in Earlier Stage NSCLC Patients

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 04 Mar 2013 03:39:28 +0000

Dr. Greg Riely from Memorial Sloan-Kettering notes how he feels molecular marker results for patients with earlier stage lung cancer can potentially be valuable.

Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 04 Mar 2013 02:12:52 +0000

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.

Dr. Karen Reckamp: Recommending a Repeat Biopsy, at Initial Diagnosis or with Acquired Resistance to a Targeted Therapy

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sun, 03 Mar 2013 08:57:11 +0000

Dr. Karen Reckamp, City of Hope Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.

Dr. WIlliam Pao on the Goals for Developing MyCancerGenome.org

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 01 Mar 2013 22:15:24 +0000

Dr. William Pao describes how the developers of MyCancerGenome.org envision the website resource being used to help cancer patients, both now and in the future.

Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 01 Mar 2013 21:25:04 +0000

Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 01 Mar 2013 01:59:31 +0000

Dr. Ravi Salgia from University of Chicago explains his approach to management of acquired resistance to a targeted therapy for advanced NSCLC, both in the setting of a single area of progression and also when disease progression is more diffuse.

Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 28 Feb 2013 01:51:42 +0000

Dr. Alan Sandler, Oregon Health and Science University, describes how he sees very specialized molecular testing for lung cancer becoming increasingly available to oncologists seeing patients in the community setting.

Dr. Phil Bonomi: Is Maintenance Therapy after First Line Chemotherapy a Mandate, An Option, or a Neither?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Thu, 28 Feb 2013 01:08:21 +0000

Dr. Phil Bonomi provides his views on the value of maintenance therapy for advanced non-small cell lung cancer and the various alternatives among maintenance therapies compared with a break from treatment.

Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 27 Feb 2013 05:42:51 +0000

Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.

Dr. Monty Pal: How Do We Work Up a Kidney Mass That May Be Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Wed, 27 Feb 2013 01:46:00 +0000

Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA reviews a recommended approach to the workup of a kidney mass suspected to be a cancer.

Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn't Enough Tissue for Molecular Testing?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 25 Feb 2013 23:23:55 +0000

Drs. Ross Camidge and Corey Langer discuss which patients with advanced NSCLC they would recommend should have a repeat biopsy if their initial tissue sample doesn't have sufficient tissue for molecular testing.

Dr. Sarah Goldberg: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 25 Feb 2013 22:18:10 +0000

Dr. Sarah Goldberg reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

Dr. Karen Kelly: What Molecular Markers Do You Routinely Send for in Your Patients with Advanced Non-Small Cell Lung Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 25 Feb 2013 00:54:37 +0000

Dr. Karen Kelly describes her thought process on which molecular markers are those clearly indicated for testing in patients with advanced NSCLC, as well as whether smoking status factors into her approach.

Dr. Heather Wakelee: Do You Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Mon, 25 Feb 2013 00:53:52 +0000

Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.

Dr. Greg Riely: How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 23 Feb 2013 23:33:24 +0000

Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.

Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Sat, 23 Feb 2013 08:33:59 +0000

Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.

Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 22 Feb 2013 22:28:13 +0000

Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.

What is an Inherited T790M EGFR Mutation, and What Does It Mean?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 22 Feb 2013 11:03:06 +0000

Dr. Geoffrey Oxnard describes the new finding of individuals with an inherited T790M mutation in the EGFR gene, the unclear significance of it, and a study being conducted to learn more about it.

What is MyCancerGenome.org?

west@cancergrace.org (cancerGRACE - H. Jack West, MD) — Fri, 22 Feb 2013 01:55:46 +0000

Dr. William Pao describes the MyCancerGenome.org website and how data on a wide range of mutations is incorporated to build this database to help physicians and cancer patients identify the most promising targeted therapy options for them.